Lexicon Pharmaceuticals (NASDAQ:LXRX) Announces Earnings Results

Lexicon Pharmaceuticals (NASDAQ:LXRX) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported $2.11 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.80, Fidelity Earnings reports. The company had revenue of $294.45 million during the quarter, compared to analyst estimates of $12.00 million. The company’s quarterly revenue was up 4124.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.26) EPS.

Shares of Lexicon Pharmaceuticals stock traded down $0.36 on Friday, hitting $3.52. 1,316,800 shares of the company’s stock traded hands, compared to its average volume of 1,292,482. Lexicon Pharmaceuticals has a one year low of $1.13 and a one year high of $9.15. The company has a fifty day moving average of $3.52 and a two-hundred day moving average of $4.21. The company has a market capitalization of $419.77 million, a price-to-earnings ratio of -3.09 and a beta of 0.95.

In other Lexicon Pharmaceuticals news, CEO Lonnel Coats purchased 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was bought at an average cost of $3.13 per share, with a total value of $156,500.00. Following the completion of the transaction, the chief executive officer now owns 127,639 shares of the company’s stock, valued at approximately $399,510.07. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher J. Sobecki purchased 25,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were acquired at an average cost of $2.55 per share, with a total value of $63,750.00. Following the completion of the transaction, the director now directly owns 112,493 shares of the company’s stock, valued at approximately $286,857.15. The disclosure for this purchase can be found here. Insiders have purchased 255,749 shares of company stock valued at $578,510 over the last ninety days. 6.40% of the stock is currently owned by company insiders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

LXRX has been the subject of several recent research reports. Citigroup cut Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price target for the company from $3.00 to $4.00 in a research note on Friday. Zacks Investment Research raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research note on Saturday. BidaskClub cut Lexicon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 5th. G.Research raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, ValuEngine raised Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $6.45.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: What is a stock split?

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Leave a Reply

Your email address will not be published. Required fields are marked *

*